Partnered Program (Lilly/Eisai)
Undisclosed
Lead IDActive
Key Facts
About Seed Therapeutics
SEED Therapeutics is a private, pre-revenue biotech developing a next-generation platform for molecular glue degraders. Its core innovation, the RITE3™ platform, seeks to unlock the full universe of over 600 human E3 ligases to rationally degrade disease proteins considered 'undruggable' by traditional modalities. The company has a lead oncology asset, ST-01156, in Phase 1 trials and a pipeline of partnered and internal programs, backed by a scientifically distinguished founding team including Nobel Laureate Avram Hershko. SEED represents a high-potential, high-risk venture aiming to expand the reach of targeted protein degradation beyond the current limitations of the field.
View full company profileTherapeutic Areas
Other Undisclosed Drugs
| Drug | Company | Phase |
|---|---|---|
| Preclinical ISAC 1 | Bolt Biotherapeutics | Preclinical |
| Preclinical ISAC 2 | Bolt Biotherapeutics | Preclinical |
| ART12.11 | Artelo Biosciences | Preclinical |
| Novel Vaccines | MSD | Development |
| SLS-009 | Seelos Therapeutics | Discovery |
| Technosphere Platform (New Formulations) | MannKind | Discovery/Preclinical |
| Measovir®-based Prophylactic Vaccine (with Unither) | Oncovita | Research/Pre-clinical |
| Internal sdAb Discovery Program | NanoTag Biotechnologies | Discovery |
| NB-701 | Nerai Biosciences | Discovery |
| Undisclosed Therapeutic Program(s) | Bright Cell | Clinical Trial (Phase unspecified) |
| Biosimilars Pipeline | Intelligent Therapeutics | Pre-clinical/Development |
| Proprietary Therapeutic Pipeline | Excelsior Sciences | Discovery |